Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014, Article ID 715908, 5 pages
http://dx.doi.org/10.1155/2014/715908
Research Article

The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes

1Division of Endocrinology, Department of Internal Medicine, Kwandong University College of Medicine, 100-25 Simgok-ro, Seo-gu, Incheon 404-834, Republic of Korea
2Division of Nephrology, Department of Internal Medicine, Kwandong University College of Medicine, 100-25 Simgok-ro, Seo-gu, Incheon 404-834, Republic of Korea
3Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of Korea

Received 21 April 2014; Revised 7 June 2014; Accepted 10 June 2014; Published 26 June 2014

Academic Editor: Andre P. Kengne

Copyright © 2014 Se Hwa Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. E. S. Poole, R. L. Van Bezooijen, N. Loveridge et al., “Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation,” FASEB Journal, vol. 19, no. 13, pp. 1842–1844, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Baron and G. Rawadi, “Minireview: targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton,” Endocrinology, vol. 148, no. 6, pp. 2635–2643, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. X. Li, Y. Zhang, H. Kang et al., “Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling,” Journal of Biological Chemistry, vol. 280, no. 20, pp. 19883–19887, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. U. I. Mödder, K. A. Hoey, S. Amin et al., “Relation of age, gender, and bone mass to circulating sclerostin levels in women and men,” Journal of Bone and Mineral Research, vol. 26, no. 2, pp. 373–379, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Amrein, S. Amrein, C. Drexler et al., “Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 1, pp. 148–154, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Garcia-Martin, P. Rozas-Moreno, and R. Reyes-Garcia, “Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 1, pp. 234–241, 2012. View at Publisher · View at Google Scholar
  7. Y. Rhee, S. J. Kim, K. J. Han, S. K. Lim, and S. H. Kim, “Effect of liver dysfunction on circulating sclerostin,” Journal of Bone and Mineral Metabolism, 2013. View at Publisher · View at Google Scholar
  8. D. Cejka, J. Herberth, A. J. Branscum et al., “Sclerostin and dickkopf-1 in renal osteodystrophy,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 4, pp. 877–882, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Pelletier, L. Dubourg, M. Carlier, A. Hadj-Aissa, and D. Fouque, “The relation between renal function and serum sclerostin in adult patients with CKD,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 5, pp. 819–823, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. F. S. Mirza, I. D. Padhi, L. G. Raisz, and J. A. Lorenzo, “Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 4, pp. 1991–1997, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Sabbagh, F. G. Graciolli, S. O'Brien et al., “Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy,” Journal of Bone and Mineral Research, vol. 27, no. 8, pp. 1757–1772, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Cejka, R. Marculescu, and N. Kozakowski, “Renal elimination of sclerostin increases with declining kidney function,” Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 1, pp. 248–255, 2014. View at Publisher · View at Google Scholar
  13. H. Keller and M. Kneissel, “SOST is a target gene for PTH in bone,” Bone, vol. 37, no. 2, pp. 148–158, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Bellido, A. A. Ali, I. Gubrij et al., “Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis,” Endocrinology, vol. 146, no. 11, pp. 4577–4583, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. H. van Lierop, J. E. Witteveen, N. A. T. Hamdy, and S. E. Papapoulos, “Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls,” European Journal of Endocrinology, vol. 163, no. 5, pp. 833–837, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Thambiah, R. Roplekar, P. Manghat et al., “Circulating sclerostin and dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): Relationship with bone density and arterial stiffness,” Calcified Tissue International, vol. 90, no. 6, pp. 473–480, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Gennari, D. Merlotti, R. Valenti et al., “Circulating Sclerostin levels and bone turnover in type 1 and type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 5, pp. 1737–1744, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. C. Ferreira, G. O. Ferrari, and K. R. Neves, “Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease—role of sclerostin?” PLoS ONE, vol. 8, no. 11, Article ID e79721, 2013. View at Publisher · View at Google Scholar
  19. S. Kirmani, S. Amin, L. K. McCready et al., “Sclerostin levels during growth in children,” Osteoporosis International, vol. 23, no. 3, pp. 1123–1130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. M. Ardawi, H. A. Al-Kadi, A. A. Rouzi, and M. H. Qari, “Determinants of serum sclerostin in healthy pre- and postmenopausal women,” Journal of Bone and Mineral Research, vol. 26, no. 12, pp. 2812–2822, 2011. View at Publisher · View at Google Scholar · View at Scopus